LENZ Therapeutics (LENZ) announced an exclusive license and commercialization agreement for Thea to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025. Thea is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products. Under the terms of the licensing and commercialization agreement, LENZ will be eligible to receive over $70M in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on net sales. Thea will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in Canada.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics Holds 2025 Annual Stockholders Meeting
- LENZ Therapeutics Prepares for LNZ100 Launch
- Lenz Therapeutics’ Earnings Call Highlights Strong Outlook
- Lenz Therapeutics, Lotus enter license, commercialization agreement for LNZ100
- LENZ Therapeutics Positioned for Success with LNZ100 Ahead of 2025 PDUFA Date